AR038700A1 - Anticuerpos monoclonales anti-tenascina humana - Google Patents

Anticuerpos monoclonales anti-tenascina humana

Info

Publication number
AR038700A1
AR038700A1 ARP030100622A ARP030100622A AR038700A1 AR 038700 A1 AR038700 A1 AR 038700A1 AR P030100622 A ARP030100622 A AR P030100622A AR P030100622 A ARP030100622 A AR P030100622A AR 038700 A1 AR038700 A1 AR 038700A1
Authority
AR
Argentina
Prior art keywords
human anti
tenascin
seq
monoclonal antibody
tenascine
Prior art date
Application number
ARP030100622A
Other languages
English (en)
Inventor
Santis Rita De
Anna Maria Anastasi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR038700A1 publication Critical patent/AR038700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un nuevo anticuerpo monoclonal ST2146 anti-tenascina humana que tiene alta afinidad con respecto al antígeno nativo y alta selectividad tumoral. El hibridoma cST2146 produce en forma estable el anticuerpo en condiciones de cultivo de alta densidad y es adecuado para el desarrollo industrial de productos basados en ST2146. El ST2146 presenta propiedades que se pueden explotar para aplicaciones terapéuticas y de diagnóstico. Reivindicación (1): Anticuerpo monoclonal anti-tenascina humana cuyas secuencias de regiones variables de cadena liviana y pesada son SEQ ID NO: 1 y SEQ ID NO: 2, respectivamente, y los fragmentos proteolíticos del mismo se ligan a un epitopo antigénico dentro de la repetición tipo EGF de la tenascina humana C.
ARP030100622A 2002-02-26 2003-02-26 Anticuerpos monoclonales anti-tenascina humana AR038700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26

Publications (1)

Publication Number Publication Date
AR038700A1 true AR038700A1 (es) 2005-01-26

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100622A AR038700A1 (es) 2002-02-26 2003-02-26 Anticuerpos monoclonales anti-tenascina humana

Country Status (20)

Country Link
US (3) US7438908B2 (es)
EP (1) EP1478667B1 (es)
JP (1) JP4488746B2 (es)
KR (1) KR101048894B1 (es)
CN (1) CN1317303C (es)
AR (1) AR038700A1 (es)
AT (1) ATE480564T1 (es)
AU (1) AU2003215900B2 (es)
BR (1) BR0307994A (es)
CA (1) CA2475395C (es)
CY (1) CY1111108T1 (es)
DE (1) DE60334076D1 (es)
DK (1) DK1478667T3 (es)
ES (1) ES2352180T3 (es)
HK (1) HK1078589A1 (es)
MX (1) MXPA04008216A (es)
PL (1) PL213216B1 (es)
PT (1) PT1478667E (es)
SI (1) SI1478667T1 (es)
WO (1) WO2003072608A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
EP2420252A1 (en) * 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
AU2010204583A1 (en) * 2009-01-15 2011-08-25 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
ES2526519T3 (es) * 2009-01-15 2015-01-13 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente por medición de la expresión HER-2
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
CA2817973C (en) * 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
CN104105967B (zh) * 2011-12-12 2017-03-08 牛津大学科技创新有限公司 生腱蛋白c及其在类风湿关节炎的用途
CN110041427B (zh) * 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU6445894A (en) * 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
JPH08510909A (ja) * 1993-05-28 1996-11-19 ザ スクリップス リサーチ インスティチュート Ｃｄ１４媒介細胞活性化を抑制するための方法および組成物
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
MXPA04008216A (es) 2004-11-26
AU2003215900B2 (en) 2008-09-25
CA2475395A1 (en) 2003-09-04
ES2352180T3 (es) 2011-02-16
KR101048894B1 (ko) 2011-07-13
DE60334076D1 (de) 2010-10-21
EP1478667B1 (en) 2010-09-08
JP2005534615A (ja) 2005-11-17
EP1478667A1 (en) 2004-11-24
CY1111108T1 (el) 2015-06-11
PT1478667E (pt) 2010-12-09
HK1078589A1 (en) 2006-03-17
AU2003215900A1 (en) 2003-09-09
US20040005643A1 (en) 2004-01-08
US7438908B2 (en) 2008-10-21
WO2003072608A1 (en) 2003-09-04
CN1317303C (zh) 2007-05-23
ATE480564T1 (de) 2010-09-15
CA2475395C (en) 2011-08-02
SI1478667T1 (sl) 2010-12-31
BR0307994A (pt) 2004-12-07
DK1478667T3 (da) 2010-12-20
CN1639192A (zh) 2005-07-13
US8048417B2 (en) 2011-11-01
US20110020219A1 (en) 2011-01-27
PL213216B1 (pl) 2013-01-31
US20050106145A1 (en) 2005-05-19
JP4488746B2 (ja) 2010-06-23
KR20040086426A (ko) 2004-10-08
PL372803A1 (en) 2005-08-08

Similar Documents

Publication Publication Date Title
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
PE20050727A1 (es) Anticuerpos dirigidos a c-met
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
HRP20090517T1 (en) Interleukin-10 antibodies
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
AR016243A1 (es) Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CO6231040A2 (es) Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20061329A1 (es) Anticuerpos ab humanizados para mejorar la cognicion
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
RS53743B1 (en) ANTI-GM-CSF ANTIBODIES AND THEIR USE
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
RS52439B (en) HUMAN ANTIBODIES TO THE HUMAN DELTA SIMILAR LIGAND 4
PE20050712A1 (es) Anticuerpos rg1
PE20071055A1 (es) Anticuerpos anti mn
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
PE20220708A1 (es) Anticuerpos anti-cd73

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee